Literature DB >> 9201603

Hyperglycemia counterbalances the antihypertensive effect of glutathione in diabetic patients: evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitus.

A Cerielo1, E Motz, A Cavarape, S Lizzio, A Russo, A Quatraro, D Giugliano.   

Abstract

Diabetes mellitus is associated with hypertension. An antihypertensive effect of the antioxidant glutathione has been recently demonstrated. It has been suggested that hyperglycemia may contribute to the pathophysiology of hypertension in diabetes by generating an oxidative stress. In this study, three different tests were performed in ten hypertensive and ten nonhypertensive diabetic subjects: (1) an oral glucose tolerance test, (2) glutathione i.v. administration (1 g/m2 bolus + 1 g/m2 in 2 h), and (3) oral glucose tolerance test + glutathione administration. At -15', 0', 30', 60', 90', 120', and 180' systolic and diastolic blood pressure, plasma glucose, and insulin were measured. Variations in plasma glucose and insulin levels were not different during each test in the two groups of patients and in test (1) compared to (3). Glutathione administration reduced systolic and diastolic blood pressure in both hypertensive and nonhypertensive diabetic subjects from 30' to 120'. This phenomenon was abolished as glycemia increased after oral glucose loading. In hypertensive, but not in nonhypertensive diabetic subjects, a significant increase of systolic and diastolic blood pressure was observed at 90' and 120' of the oral glucose tolerance test (p < 0.01). These data show that hyperglycemia can counteract the hypotensive effects of the antioxidant glutathione, suggesting that glucose may impair arterial relaxation by producing free radicals. Also, it appears that hypertension in diabetic patients is aggravated by high glucose plasma levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9201603     DOI: 10.1016/s1056-8727(97)00021-4

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  6 in total

1.  Effect of acute hyperglycemia on potassium (86Rb+) permeability and plasma lipid peroxidation in subjects with normal glucose tolerance.

Authors:  M Güven; I Onaran; T Ulutin; G Sultuybek; H Hatemi
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

2.  Effect of acute hyperglycemia on potassium (86Rb+) permeability and plasma lipid peroxidation in subjects with normal glucose tolerance.

Authors:  M Güven; I Onaran; T Ulutin; G Sultuybek; H Hatemi
Journal:  J Endocrinol Invest       Date:  2001-04       Impact factor: 4.256

3.  Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients.

Authors:  Ondrej Zitka; Sylvie Skalickova; Jaromir Gumulec; Michal Masarik; Vojtech Adam; Jaromir Hubalek; Libuse Trnkova; Jarmila Kruseova; Tomas Eckschlager; Rene Kizek
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

4.  Increased systemic Th17 cytokines are associated with diastolic dysfunction in children and adolescents with diabetic ketoacidosis.

Authors:  William H Hoffman; Gregory G Passmore; David W Hannon; Monica V Talor; Pam Fox; Catherine Brailer; Dynita Haislip; Cynthia Keel; Glenn Harris; Noel R Rose; Irma Fiordalisi; Daniela Čiháková
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

5.  Beneficial effects of oral pure caffeine on oxidative stress.

Authors:  Daniela Metro; Valeria Cernaro; Domenico Santoro; Mattia Papa; Michele Buemi; Salvatore Benvenga; Luigi Manasseri
Journal:  J Clin Transl Endocrinol       Date:  2017-10-13

6.  Characterization of blood oxidative stress in type 2 diabetes mellitus patients: increase in lipid peroxidation and SOD activity.

Authors:  Suziy de M Bandeira; Glaucevane da S Guedes; Lucas José S da Fonseca; André S Pires; Daniel P Gelain; José Claudio F Moreira; Luíza A Rabelo; Sandra Mary L Vasconcelos; Marília Oliveira F Goulart
Journal:  Oxid Med Cell Longev       Date:  2012-11-08       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.